Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction (Cellgram-ED)
A Safety Follow-up Study of a Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Cellgram-ED (Autologous Bone Marrow-Derived Mesenchymal Stem Cells) in Patients With Post-Radical Prostatectomy Erectile Dysfunction
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: daeun jung
- Phone Number: 82-2-3496-0134
- Email: daeun4100@pharmicell.com
Study Locations
-
-
-
Seoul, South Korea
- Recruiting
- Samsung Medical Center
-
Contact:
- Deokhyun Han
- Phone Number: 82-2-3410-6431
- Email: deokhyun.han@gmail.com
-
Seoul, South Korea
- Recruiting
- Asan Medical Center
-
Contact:
- Bumjin Im
- Phone Number: 82-2-3010-1835
- Email: lbj1986@hanmail.net
-
Seoul, South Korea
- Recruiting
- Ewha Womans University Medical Center
-
Contact:
- Kim Chungsu
- Phone Number: 82-10-2297-3734
- Email: cskim37345806@gmail.com
-
Seoul, South Korea
- Recruiting
- Seoul St. Mary'S Hospital
-
Contact:
- Jiyoul Lee
- Phone Number: 82-2-2258-6227
- Email: uroljy@catholic.ac.kr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants who previously participated in the parent clinical trial and received the cell therapy (Cellgram-ED).
- Participants who have provided written informed consent to participate in this safety follow-up study.
Exclusion Criteria:
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cellgram-ED Safety Follow-up Group
Participants in this arm previously received Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) via intracavernous injection in the parent phase II clinical trial.
This safety follow-up study monitors these participants for long-term safety outcomes for up to 4 years (±30 days) from the completion of the parent trial, including assessment of adverse events and other clinically relevant safety parameters.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tumor Marker Levels
Time Frame: Baseline and annually for up to 5 years after enrollment in the long-term follow-up study.
|
Long-term safety will be evaluated by assessing changes in tumor marker levels including prostate-specific antigen (PSA), alpha-fetoprotein (AFP), and carcinoembryonic antigen (CEA) during the safety follow-up period.
|
Baseline and annually for up to 5 years after enrollment in the long-term follow-up study.
|
|
Serious Adverse Events
Time Frame: From enrollment in the long-term follow-up study through 5 years of follow-up.
|
The number of participants experiencing serious adverse events during the safety follow-up period.
|
From enrollment in the long-term follow-up study through 5 years of follow-up.
|
|
New Cancer Development
Time Frame: From enrollment in the long-term follow-up study through 5 years of follow-up.
|
The number of participants with newly diagnosed malignancies during the safety follow-up period.
|
From enrollment in the long-term follow-up study through 5 years of follow-up.
|
|
Prostate Cancer Recurrence
Time Frame: From enrollment in the long-term follow-up study through 5 years of follow-up.
|
The number of participants with recurrence of prostate cancer during the safety follow-up period.
|
From enrollment in the long-term follow-up study through 5 years of follow-up.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bumjin Lim, Ph.D, AIDS Malignancy Consortium
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PMC-P-10-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.